XVARY Composite Score
55
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
It develops experimental cancer and brain-disease drugs from one research platform.
How it gets paid
Last year Immuneering made n/a in revenue. IMM-1-104 was the main engine at $0M, or 25% of sales.
What just happened
The latest quarter showed a -$1.20 EPS loss, with no revenue to lean on.
At a Glance
B balance sheet — gets the job done, barely
-$2.04 fy2024 eps est
$0M fy2022 rev est
1.05 beta
~$326M market cap
XVARY composite: 55/100 — below average
What They Do
It develops experimental cancer and brain-disease drugs from one research platform.
The moat is a pipeline, not sales. IMM-1-104 is in Phase 1/2a, which means first human testing. Six other oncology programs are still in discovery. You are looking at 7 shots on goal, and only 1 has reached patients.
How They Make Money
n/a
annual revenue
IMM-1-104
$0M
IMM-6-415
$0M
Other oncology discovery programs
$0M
Neuroscience programs
$0M
The Products That Matter
Pancreatic cancer drug candidate
lead pancreatic cancer candidate
$0M revenue · 64% survival at 12 months
this program has no sales, but it carries most of the $326M equity story. If that 64% survival signal holds up, the stock has a case. If it does not, the platform looks a lot less valuable.
lead asset
Computational drug discovery platform
translational bioinformatics platform
$0M revenue · pre-commercial
the platform is the engine behind candidate selection, but it has generated $0 in partnership or product revenue. Right now it is a research tool, not a proven business line.
platform bet
Key Numbers
$326M
market cap
You are paying $326M for a company with $0M revenue.
5/100
stability score
A 5/100 stability score means the shares do not sit still.
$4M
debt
Long-term debt is $4M, or 1% of capital. That is not the main problem.
1.05
beta
A 1.05 beta means it moves a bit more than the market.
Financial Health
B
Strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $4M (1% of capital)
B — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
The latest quarter showed a -$1.20 EPS loss, with no revenue to lean on.
The company is still a pre-revenue biotech. That means the quarter was about cash burn, not sales growth.
$0M
revenue
-$1.20
eps
n/a
n/a
per-share loss
The -$1.20 per-share loss matters because there is still $0 of product revenue underneath it.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk is failure of the lead pancreatic cancer program to hold up in later data.
Med
The lead trial disappoints
A $326M valuation is sitting on one core clinical story. If the 64% survival signal at 12 months weakens, the market will not grade on a curve.
impact: it would directly hit the only asset currently supporting the equity case.
Med
Dilution arrives before proof
With $0M in revenue and expected losses of -$2.04 per share, operating cash has to come from the balance sheet or new capital. That is biotech math, not a management preference.
impact: if capital is raised before a stronger readout, your ownership percentage gets smaller before the science gets better.
Med
The platform narrative stays a narrative
The computational discovery angle sounds appealing. It still produces $0M of partnership or product revenue today. Until more assets or outside validation show up, the platform has to live off the lead program's credibility.
impact: if investors stop paying for platform optionality, the stock gets valued as a single-asset biotech. Because that is what it is.
a negative readout would hit the one asset behind a $326M market cap, and the lack of revenue means there is no operating business to absorb the blow.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Catalyst
Next meaningful clinical readout
This is the whole story. You want evidence that the 64% survival figure at 12 months is repeatable, durable, and not a one-off headline.
Cash math
Loss trajectory versus runway
Q4 2025 EPS of -$0.18 was better than the -$0.31 estimate. Smaller losses matter because this company has $0M in revenue and every quarter bought is extra time for the science.
Risk
Equity raise risk
A B balance sheet and just $4M of long-term debt look fine on the surface. The real question is whether fresh capital shows up before stronger data does.
Trading behavior
Volatility staying extreme
A 52-week range of $1–$10 and price stability of 5 / 100 tell you this name is still trading as an event stock. If volatility stays this high, the market still sees probability, not proof.
Analyst Rankings
coverage depth
thin
At a $326M market cap with no published target range on this page, coverage looks limited. in human-speak, this stock is being priced more by trial odds than by a crowded analyst model stack.
market risk
1.05
Beta of 1.05 says the stock roughly tracks the market on a spreadsheet. The 52-week range of $1–$10 says clinical headlines matter more than index moves.
stability
5 / 100
Price stability is near the floor. That usually means investors are constantly repricing a small set of binary outcomes.
Source: institutional data
Institutional Activity
institutional ownership data for IMRX is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$5
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive